

Burosumab-twza (Crysvita)

Provider Order Form rev. 01/02/2024

PATIENT INFORMATION

Referral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal

Patient Name:	DOB:	Patient Phone:
Patient Address:	Patient Email:	
Allergies:	<input type="checkbox"/> NKDA	Weight (lbs/kg): Height (in/cm):
Sex: <input type="checkbox"/> M / <input type="checkbox"/> F	Date of Last Infusion:	Next Due Date: Preferred Location:

DIAGNOSIS (Please provide ICD-10 code in space provided)

Familial hypophosphatemia:	Other disorders of phosphorus metabolism:
Tumor Induced Osteomalacia:	X-linked hypophosphatemia:
Other diagnosis:	

THERAPY ADMINISTRATION

- ☒ Administer Crysvita _____ mg (round to nearest 10 mg) subcutaneously in the upper arm/abdomen/upper thigh. Maximum volume per site is 1.5 ml
- ☒ Following initial treatment, observe patient for 15 minutes for hypersensitivity

DOSING INFORMATION

Dosing information for Adults:

- XLH: 10mg-90mg max (usually 1mg/kg) max 90mg every 4 weeks
- TIO: 0.5mg/kg to 2mg/kg max of 180mg every 2 weeks

Dose adjustments should not occur more frequently than every 4 weeks

FREQUENCY (Choose one)

- ☐ Every 2 weeks
☐ Every 4 weeks

LABORATORY ORDERS

- ☒ Patient has been provided with lab order and instructions to assess fasting serum phosphorus on a monthly basis, measured 2 weeks post-dose, for the first 3 months of treatment, and thereafter as appropriate.

PRE-MEDICATION ORDERS

- ☐ Other: _____

NURSING

- ☒ Serum phosphorus at initiation of therapy: _____ mg/dL
Date: _____
- ☒ Hold infusion and notify provider for:
- Serum phosphorus within or above normal range at **initiation of therapy**
 - Serum phosphorus above normal range for patients **already on therapy**
 - Pt reports taking oral phosphate and/or active vitamin D analogs (e.g. calcitriol, paricalcitol, doxercalciferol, calcifediol) within 1 week prior to initiation of treatment
 - Ensure that provider is monitoring 25-hydroxy-vitamin D levels.
 - CrCl<30
- ☒ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation

ADDITIONAL ORDERS

PROVIDER INFORMATION

Preferred Contact Name:	Preferred Contact Email:
Ordering Provider:	Provider NPI:
Referring Practice Name:	Phone: Fax:
Practice Address:	City: State: Zip Code:

REQUIRED DOCUMENTATION CHECKLIST (Additional documentation required for processing and insurance approval)

Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN including treatment failures or contraindications, radiology results

Required Labs: Genetic testing to confirm a phosphate regulating gene mutation, FGF23, phosphorus levels

Provider Name (print)

Provider Signature

Date

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.